Senator Investment Group’s Neurocrine Biosciences NBIX Stock Holding History

Senator Investment Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-155,000	Closed	-$15.1M	–	134
2021 Q1	$15.1M	Buy	+155,000	New	+$16.3M	0.31%	66
2019 Q1	–	Sell	-300,000	Closed	-$21.4M	–	43
2018 Q4	$21.4M	Buy	+300,000	New	+$28.7M	0.6%	29
2017 Q2	–	Sell	-900,000	Closed	-$39M	–	64
2017 Q1	$39M	Buy	900,000 +25,000	+3%	+$1.07M	0.48%	47
2016 Q4	$33.9M	Sell	875,000 -275,000	-24%	-$12.4M	0.51%	35
2016 Q3	$58.2M	Buy	1,150,000 +300,000	+35%	+$14.9M	0.77%	36
2016 Q2	$38.6M	Buy	+850,000	New	+$39.1M	0.62%	39

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

DCP

DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

Senator Investment Group's NBIX Position: Q2 2021 in Review

Senator Investment Group sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 155,000 shares — an estimated $15.1M sold.

Senator Investment Group first reported a position in NBIX in Q2 2016 and held it in 6 quarters. The position peaked at $58.2M in Q3 2016. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

Senator Investment Group reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
Senator Investment Group sold 155,000 Neurocrine Biosciences shares in Q2 2021, an estimated $15.1M.
Senator Investment Group first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 6 quarters.
Senator Investment Group's Neurocrine Biosciences position peaked at $58.2M in Q3 2016.
408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Senator Investment Group's 13F filing for Q2 2021, filed 13 Aug 2021.